There have been 50 recent insider transactions recorded for Genelux Corporation (GNLX), including 19 buys and 27 sells. Total insider buying was valued at $6.55M and total insider selling at $8.84M.
Notable insiders with recent activity include Smalling Ralph, Yu Yong, Zindrick Thomas. Insider transactions can provide insights into how company leadership views the stock's valuation and future prospects.
Insider Transactions — GNLX
| Date |
Name |
Role |
Transaction |
Shares |
Avg. Price |
Value |
Shares Owned |
| 2026-03-25 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
240 |
$2.51 |
$602.40 |
68,073 |
| 2026-03-24 |
Yu Yong |
SVP, Clinical Development |
Informative Sell |
906 |
$2.42 |
$2.19K |
144,938 |
| 2026-03-24 |
Zindrick Thomas |
President and CEO |
Informative Sell |
3,582 |
$2.42 |
$8.67K |
534,849 |
| 2026-03-24 |
Cappello Joseph |
Chief Technical Officer |
Informative Sell |
906 |
$2.42 |
$2.19K |
155,154 |
| 2026-03-24 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
345 |
$2.42 |
$834.90 |
68,313 |
| 2026-03-02 |
Thomas John |
Director |
Informative Sell |
10,000 |
$2.90 |
$28.96K |
482,784 |
| 2026-01-02 |
Litten Jason |
Officer |
Unknown |
- |
- |
- |
- |
| 2026-01-02 |
Litten Jason |
Chief Medical Officer |
RSU Award |
275,000 |
$4.55 |
$1.25M |
275,000 |
| 2025-12-05 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
165 |
$4.69 |
$773.85 |
68,658 |
| 2025-12-01 |
Thomas John |
Director |
Informative Sell |
10,000 |
$5.00 |
$50.01K |
492,784 |
| 2025-11-17 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
343 |
$5.37 |
$1.84K |
68,823 |
| 2025-11-17 |
Yu Yong |
SVP, Clinical Development |
Informative Sell |
973 |
$5.37 |
$5.22K |
145,844 |
| 2025-11-17 |
Zindrick Thomas |
President and CEO |
Informative Sell |
4,509 |
$5.37 |
$24.21K |
538,431 |
| 2025-11-17 |
Cappello Joseph |
Chief Technical Officer |
Informative Sell |
973 |
$5.37 |
$5.22K |
156,060 |
| 2025-09-03 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
580 |
$3.36 |
$1.95K |
69,166 |
| 2025-09-01 |
Yu Yong |
SVP, Clinical Development |
Return of Shares |
65,000 |
$22.40 |
$1.46M |
- |
| 2025-09-01 |
Zindrick Thomas |
President and CEO |
Return of Shares |
250,000 |
$22.40 |
$5.6M |
- |
| 2025-09-01 |
Cappello Joseph |
Chief Technical Officer |
Return of Shares |
65,000 |
$22.40 |
$1.46M |
- |
| 2025-09-01 |
Smalling Ralph |
Head of Regulatory |
Return of Shares |
8,333 |
$6.00 |
$50K |
- |
| 2025-08-27 |
Tyree James L |
Director |
RSU Award |
28,576 |
$3.64 |
$104.02K |
28,576 |
| 2025-08-27 |
Smither John W |
Director |
RSU Award |
28,576 |
$3.64 |
$104.02K |
28,576 |
| 2025-08-27 |
Yu Yong |
SVP, Clinical Development |
RSU Award |
134,520 |
$3.64 |
$489.65K |
134,520 |
| 2025-08-27 |
Mirabelli Mary |
Director |
RSU Award |
28,576 |
$3.64 |
$104.02K |
28,576 |
| 2025-08-27 |
Zindrick Thomas |
President and CEO |
RSU Award |
478,800 |
$3.64 |
$1.74M |
478,800 |
| 2025-08-27 |
Thomas John |
Director |
RSU Award |
28,576 |
$3.64 |
$104.02K |
28,576 |
| 2025-08-27 |
Cappello Joseph |
Chief Technical Officer |
RSU Award |
142,500 |
$3.64 |
$518.7K |
142,500 |
| 2025-08-27 |
Smalling Ralph |
Head of Regulatory |
RSU Award |
34,770 |
$3.64 |
$126.56K |
34,770 |
| 2025-08-21 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
1,244 |
$3.36 |
$4.18K |
69,746 |
| 2025-08-21 |
Yu Yong |
SVP, Clinical Development |
Informative Sell |
3,219 |
$3.36 |
$10.81K |
146,817 |
| 2025-08-21 |
Zindrick Thomas |
President and CEO |
Informative Sell |
12,673 |
$3.33 |
$42.16K |
542,940 |
| 2025-08-21 |
Cappello Joseph |
Chief Technical Officer |
Informative Sell |
1,463 |
$3.36 |
$4.91K |
157,033 |
| 2025-07-01 |
Groen Eric |
Officer |
Unknown |
- |
- |
- |
- |
| 2025-07-01 |
Groen Eric |
General Counsel & Secretary |
RSU Award |
270,000 |
$2.83 |
$764.1K |
270,000 |
| 2025-06-06 |
Thomas John |
Director |
Gift (Given) |
25,000 |
- |
- |
480,501 |
| 2025-05-12 |
Yu Yong |
VP, Clinical Trial Operations |
Informative Sell |
5,579 |
$2.92 |
$16.29K |
47,640 |
| 2025-05-12 |
Ryder Sean |
General Counsel |
Informative Sell |
4,475 |
$2.92 |
$13.07K |
47,621 |
| 2025-05-12 |
Zindrick Thomas |
President and CEO |
Informative Sell |
10,764 |
$2.92 |
$31.43K |
191,447 |
| 2025-05-12 |
Cappello Joseph |
VP, Pharmaceutical Development |
Informative Sell |
4,737 |
$2.92 |
$13.83K |
52,266 |
| 2025-05-12 |
Smalling Ralph |
Head of Regulatory |
Informative Sell |
1,259 |
$2.92 |
$3.68K |
34,760 |
| 2025-03-14 |
Yu Yong |
VP, Clinical Trial Operations |
RSU Award |
13,350 |
- |
- |
53,219 |
| 2025-03-14 |
Ryder Sean |
General Counsel |
RSU Award |
10,708 |
- |
- |
52,096 |
| 2025-03-14 |
Zindrick Thomas |
President and CEO |
RSU Award |
30,339 |
- |
- |
202,211 |
| 2025-03-14 |
Cappello Joseph |
VP, Pharmaceutical Development |
RSU Award |
13,350 |
- |
- |
57,003 |
| 2025-03-14 |
Smalling Ralph |
Head of Regulatory |
RSU Award |
4,172 |
- |
- |
36,019 |
| 2025-01-31 |
Pulisic Matthew |
Chief Financial Officer |
RSU Award |
275,000 |
$3.95 |
$1.09M |
275,000 |
| 2025-01-30 |
Pulisic Matthew |
Officer |
Unknown |
- |
- |
- |
- |
| 2024-12-30 |
Tyree James L |
Director |
Informative Sell |
3,460 |
$2.46 |
$8.51K |
45,791 |
| 2024-12-18 |
Yu Yong |
VP, Clinical Trial Operations |
RSU Award |
39,000 |
$2.29 |
$89.31K |
39,000 |
| 2024-12-18 |
Ryder Sean |
General Counsel |
RSU Award |
30,000 |
$2.29 |
$68.7K |
30,000 |
| 2024-12-18 |
Zindrick Thomas |
President and CEO |
RSU Award |
134,500 |
- |
- |
171,872 |
■ Informative Buy/Sell — open market transaction (most significant)
■ Uninformative Buy — award, option exercise, conversion
■ Uninformative Sell — tax withholding, award vest sale
■ Neutral — gift, trust, expiry
